221122-22-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Chloro-phenyl)-3-oxo-butyric acid ethyl ester is utilized as a key building block in the production of a variety of drugs and pharmaceuticals. Its role in drug synthesis is pivotal, contributing to the development of new medications and enhancing the therapeutic potential of existing ones.
Used in Chemical Research:
In the realm of chemical research, 4-(3-Chloro-phenyl)-3-oxo-butyric acid ethyl ester is employed as a versatile compound for the exploration and development of new chemical entities. Its unique structure allows researchers to investigate its reactivity, stability, and potential interactions with other molecules, thereby expanding the horizons of organic synthesis and medicinal chemistry.
Used in Organic Synthesis:
4-(3-Chloro-phenyl)-3-oxo-butyric acid ethyl ester may also find applications in the field of organic synthesis, where it can be used to create a range of organic compounds. Its chlorophenyl group and ester functionality provide a platform for further chemical modifications, making it a promising candidate for the synthesis of complex organic molecules with specific properties and applications.
Used in Medicinal Chemistry:
Due to its structural features and reactivity, 4-(3-Chloro-phenyl)-3-oxo-butyric acid ethyl ester holds potential in medicinal chemistry for the design and synthesis of bioactive molecules. It can be a starting material or a component in the construction of pharmaceutical agents targeting various therapeutic areas, thereby contributing to the advancement of novel treatments and therapies.

Upstream product

• 64-17-5 ethanol 
• 1621689-63-1 C₁₄H₁₃ClO₅ 
• 41904-39-6 3-chloro-benzeneacetyl chloride 
• 1878-65-5 3-chlorophenylacetic acid 
• 2033-24-1 cycl-isopropylidene malonate 
• 6148-64-7 ethyl potassium malonate 
• 221121-26-2 2-(3-chloro-phenyl)-1-imidazol-1-yl-ethanone 

Downstream Products

• 871569-77-6 3-[2-(3-chlorophenyl)acetyl]-6-hydroxymethyl-2-oxo-2H-1-benzopyran-2-one 
• 1159576-74-5 ethyl (2Z)-3-amino-4-(3-chlorophenyl)but-2-enoate 
• 221121-50-2 6-(3-chloro-benzyl)-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 

Relevant academic research and scientific papers

MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS

Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth

Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor

Bioisosteric replacement of acylureido moiety in 6-acylureido-3- pyrrolylmethylidene-2-oxoindoline derivatives resulted in a series of malonamido derivatives with indolin-2-one scaffold (11-14). Further conformational restrictions of the malonamido moiety led to 2-oxo-1,2-dihydropyridine (21-25) or a 4-oxo-1,4-dihydropyridine derivatives (31-36). 4-Oxo-1,4-dihydropyridine derivatives were more potent Aurora B inhibitors than their 2-oxo-1,2- dihydropyridine counterparts and demonstrated cytotoxicities against A549 and HepG2 cells in the submicromolar range. In A549 cells, 31h decreased phosphorylation of histone H3, triggered polyploidy, induced expression of pro-apoptotic Fas and FasL with subsequent activation of caspase 8, resulting into apoptosis. In a Huh7-xenograft mouse model, 31h demonstrated potent in vivo efficacy with a daily dose of 5 mg/kg.

3,6-Disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa

In this work, coumarins were screened on thrombin (THR) and factor Xa (FXa), two of the most promising targets for the development of anticoagulant drugs. This allowed us to highlight compound 30, characterized by a 2,5-dichlorophenyl ester in the 3-position and a chloromethyl moiety in the 6-position, as a very potent THR inhibitor (ki/KI = 37 000 M-1 s-1). Moreover, this compound exhibits good selectivity over FXa (168-fold) and trypsin (54-fold). The mechanism of inactivation was investigated in this series and significantly differs from that previously observed with α-chymotrypsin. Indeed, the addition of hydrazine on the THR-inhibitor complex promotes a partial induced THR reactivation. This reactivation, confirmed by LC/MS, showed the resurgence of the native THR and a new dihydrazide complex. Docking experiments were then efficiently used to explain the trends observed in the enzymatic assays as well as to corroborate the postulated inhibition mechanism. Finally, the cell permeability of our derivatives was estimated using a computational approach.

5-alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin- 4(3H)-ones: Novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives

Molecular modeling analysis of compounds belonging to the recently published series of dihydro-alkoxy-benzyl-oxopyrimidines (DABOs), such as S- DABOs and DATNOs, gave support to the design of new 2,6-disubstituted benzyl- DABO derivatives as highly potent